# v4.21\n\n## Related releases\n\n## Data changes\n

### Gene

```
ABCB1 Summary Updated
ABCB1 Background Updated
ACVR2A Background Updated
ACVR2A Summary Updated
ADGRA2 Background Updated
ADGRA2 Summary Updated
ART1 Background Updated
ART1 Summary Updated
BCL2L2 Background Updated
BCL2L2 Summary Updated
ELL2 Summary Updated
ELL2 Background Updated
FANCI Background Updated
FANCI Summary Updated
MET Summary Updated
TLE2 Background Updated
USP1 Summary Updated
USP1 Background Updated
XPA Background Updated
XPA Summary Updated
```

### Alteration

```
ACVR2A Truncating Mutation, Mutation Effect, Description Updated
ACVR2A Truncating Mutation, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
ACVR2A Truncating Mutation, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
ACVR2A Truncating Mutation Added
ALK R3HDM2-ALK Fusion, Mutation Effect, Description Updated
ALK R3HDM2-ALK Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ALK R3HDM2-ALK Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ALK R3HDM2-ALK Fusion Added
ALK R1275L, Mutation Effect, Description Updated
ALK F1245Y, Mutation Effect, Description Updated
ALK F1245Y, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ALK F1245Y, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ALK F1174C, Mutation Effect, Description Updated
ALK F1174L, Mutation Effect, Description Updated
ALK F1245V, Mutation Effect, Description Updated
ALK F1245Y Added
ALK F1174C, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old: Inconclusive
ALK F1174C, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Resistance
ALK R1275L, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old: Inconclusive
ALK R1275L, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Resistance
ART1 Amplification, Mutation Effect, Description Updated
ART1 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ART1 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ART1 Amplification Added
BCL2L2 Amplification, Mutation Effect, Description Updated
BCL2L2 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
BCL2L2 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
BCL2L2 Amplification Added
BRAF T599dup, Mutation Effect, Description Updated
BRCA2 V1610M, Mutation Effect, Description Updated
BRCA2 V1610M, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
BRCA2 V1610M, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
BRCA2 V1610M Added
BRCA2 Y42C, Mutation Effect, Description Updated
CALR 309_417del [Exon 9 in-frame deletions] Name Changed
	 New: 309_417del [Exon 9 in-frame deletions]
	 Old: 309_417ins [Exon 9 in-frame insertions], 309_417del [Exon 9 in-frame deletions]
CALR 309_417ins [Exon 9 in-frame insertions], Mutation Effect, Description Updated
CALR 309_417ins [Exon 9 in-frame insertions], Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
CALR 309_417ins [Exon 9 in-frame insertions], Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
CALR 309_417ins [Exon 9 in-frame insertions] Added
CEBPA P272_R358ins [bZIP Region In-Frame Insertions], Mutation Effect, Description Updated
CEBPA R300G, Mutation Effect, Description Updated
EGFR S645C, Mutation Effect, Description Updated
ELL2 Deletion, Mutation Effect, Description Updated
ELL2 T298A, Mutation Effect, Description Updated
ELL2 T298A, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
ELL2 T298A, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ELL2 T298A Added
ELL2 Deletion Added
ELL2 Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old: Inconclusive
ELL2 Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Inconclusive
ERBB2 770_831del [Exon 20 in-frame deletions], Mutation Effect, Description Updated
ERBB2 770_831ins [Exon 20 in-frame insertions] Name Changed
	 New: 770_831ins [Exon 20 in-frame insertions]
	 Old: 770_831del [Exon 20 in-frame deletions], 770_831ins [Exon 20 in-frame insertions]
ERBB2 770_831del [Exon 20 in-frame deletions], Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
ERBB2 770_831del [Exon 20 in-frame deletions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ERBB2 770_831del [Exon 20 in-frame deletions] Added
GLI1 GLI1-ACTB Fusion, Mutation Effect, Description Updated
GLI1 GLI1-ACTB Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
GLI1 GLI1-ACTB Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
GLI1 GLI1-ACTB Fusion Added
GLI1 GLI1-MALAT1 Fusion, Mutation Effect, Description Updated
GLI1 GLI1-MALAT1 Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
GLI1 GLI1-MALAT1 Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
GLI1 GLI1-MALAT1 Fusion Added
GLI1 GLI1-PTCH1 Fusion, Mutation Effect, Description Updated
GLI1 GLI1-PTCH1 Fusion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
GLI1 GLI1-PTCH1 Fusion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
GLI1 GLI1-PTCH1 Fusion Added
GLI1 ACTB-GLI1 Fusion Name Changed
	 New: ACTB-GLI1 Fusion
	 Old: GLI1-ACTB Fusion
GLI1 ACTB-GLI1 Fusion, Mutation Effect, Description Updated
GLI1 MALAT1-GLI1 Fusion Name Changed
	 New: MALAT1-GLI1 Fusion
	 Old: GLI1-MALAT1 Fusion
GLI1 MALAT1-GLI1 Fusion, Mutation Effect, Description Updated
GLI1 PTCH1-GLI1 Fusion Name Changed
	 New: PTCH1-GLI1 Fusion
	 Old: GLI1-PTCH1 Fusion
GLI1 PTCH1-GLI1 Fusion, Mutation Effect, Description Updated
JAK2 505_547mis [Exon 12 missense mutations], Mutation Effect, Description Updated
JAK2 505_547mis [Exon 12 missense mutations], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
JAK2 505_547mis [Exon 12 missense mutations] Added
JAK2 505_547ins [Exon 12 in-frame insertions], Mutation Effect, Description Updated
JAK2 505_547ins [Exon 12 in-frame insertions], Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
JAK2 505_547ins [Exon 12 in-frame insertions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
JAK2 505_547ins [Exon 12 in-frame insertions] Added
JAK2 505_547del [Exon 12 in-frame deletions], Mutation Effect, Description Updated
JAK2 505_547del [Exon 12 in-frame deletions], Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
JAK2 505_547del [Exon 12 in-frame deletions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
JAK2 505_547del [Exon 12 in-frame deletions] Added
MET R1327C, Mutation Effect, Description Updated
MET R1327C, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
MET R1327C, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
MET R1327C Promoted
MET M1229V, Mutation Effect, Description Updated
MET M1229V, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
MET M1229V, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
MET M1229V Promoted
MET I1345T, Mutation Effect, Description Updated
MET I1345T, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
MET I1345T, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
MET I1345T Promoted
MET N1100S, V1092I, H1106D, R1170Q, M1250T Added
MET V1092I, Mutation Effect, Description Updated
MET L1195V, Mutation Effect, Description Updated
MET Y1230H, Mutation Effect, Description Updated
MET M1250T, Mutation Effect, Description Updated
MET H1094Y, Mutation Effect, Description Updated
MET F1200I, Mutation Effect, Description Updated
MET H1106D, Mutation Effect, Description Updated
MET H1106D, Mutation Effect, Effect Updated
	 New: Gain-of-function
	 Old: Likely Gain-of-function
MET H1106D, Mutation Effect, Oncogenic Updated
	 New: Yes
	 Old: Likely
MET D1228N, Mutation Effect, Description Updated
MET D1228N, Mutation Effect, Effect Updated
	 New: Gain-of-function
	 Old: Likely Gain-of-function
MET D1228N, Mutation Effect, Oncogenic Updated
	 New: Yes
	 Old: Likely
MET N1100S, Mutation Effect, Description Updated
MET N1100S, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old: Inconclusive
MET N1100S, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Inconclusive
MET R1170Q, Mutation Effect, Description Updated
MET R1170Q, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET R1170Q, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET R1170Q Added
MET N1081S, Mutation Effect, Description Updated
MET N1081S, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
MET N1081S, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
MET N1081S Added
MET G1102D, Mutation Effect, Description Updated
MET G1102D, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
MET G1102D, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
MET G1102D Added
MET 981_1028splice, Mutation Effect, Description Updated
MET 981_1028splice, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET 981_1028splice, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET 981_1028splice Added
MET 963_1010splice, Mutation Effect, Description Updated
MET 963_1010splice, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET 963_1010splice, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET 963_1010splice Added
MET X963_splice, Mutation Effect, Description Updated
MET X963_splice, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET X963_splice, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET X963_splice Added
MET X1006_splice, Mutation Effect, Description Updated
MET X1006_splice, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET X1006_splice, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET X1006_splice Added
MET X1007_splice, Mutation Effect, Description Updated
MET X1007_splice, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET X1007_splice, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET X1007_splice Added
MET X1008_splice, Mutation Effect, Description Updated
MET X1008_splice, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET X1008_splice, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET X1008_splice Added
MET X1009_splice, Mutation Effect, Description Updated
MET X1009_splice, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET X1009_splice, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET X1009_splice Added
MET X1010_splice, Mutation Effect, Description Updated
MET X1010_splice, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET X1010_splice, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET X1010_splice Added
MET 963_1010del [Exon 14 in-frame deletions], Mutation Effect, Description Updated
MET 963_1010del [Exon 14 in-frame deletions], Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET 963_1010del [Exon 14 in-frame deletions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET 963_1010del [Exon 14 in-frame deletions] Added
MET Exon 14 Deletion, Mutation Effect, Description Updated
MET Exon 14 Deletion, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
MET Exon 14 Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
MET Exon 14 Deletion Added
MET 981_1028splice, 963_1010splice [Exon 14 splice mutations], X963_splice, X1006_splice, X1007_splice, X1008_splice, X1009_splice, X1010_splice Deleted
PDGFRA 311_848del Name Changed
	 New: 311_848del
	 Old: 311_848ins, 311_848del
PDGFRA 311_848ins, Mutation Effect, Description Updated
PDGFRA 311_848ins, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PDGFRA 311_848ins, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
PDGFRA 311_848ins Added
PDGFRA 814_852mis [Exon 18 missense mutations], Mutation Effect, Description Updated
PDGFRA 814_852mis [Exon 18 missense mutations], Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PDGFRA 814_852mis [Exon 18 missense mutations], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
PDGFRA 814_852mis [Exon 18 missense mutations] Added
PDGFRA 814_852del [Exon 18 in-frame deletions], Mutation Effect, Description Updated
PDGFRA 814_852del [Exon 18 in-frame deletions], Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PDGFRA 814_852del [Exon 18 in-frame deletions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
PDGFRA 814_852del [Exon 18 in-frame deletions] Added
PDGFRA 814_852ins [Exon 18 in-frame insertions], Mutation Effect, Description Updated
PDGFRA 814_852ins [Exon 18 in-frame insertions], Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PDGFRA 814_852ins [Exon 18 in-frame insertions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
PDGFRA 814_852ins [Exon 18 in-frame insertions] Added
PTEN G251V, Mutation Effect, Description Updated
PTEN G251V, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old: Likely Neutral
PTEN G251V, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Likely Neutral
TFE3 YAP1-TFE3 Fusion Deleted
TP53 V218dup, Mutation Effect, Description Updated
TP53 V218dup, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
TP53 V218dup, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
TP53 V218dup Added
TP53 102_292mis [DNA binding domain missense mutations], Mutation Effect, Description Updated
TP53 102_292mis [DNA binding domain missense mutations], Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
TP53 102_292mis [DNA binding domain missense mutations], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
TP53 102_292mis [DNA binding domain missense mutations] Added
TP53 102_292ins [DNA binding domain insertions], Mutation Effect, Description Updated
TP53 102_292ins [DNA binding domain insertions], Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
TP53 102_292ins [DNA binding domain insertions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
TP53 102_292ins [DNA binding domain insertions] Added
TP53 102_292del [DNA binding domain deletions], Mutation Effect, Description Updated
TP53 102_292del [DNA binding domain deletions], Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
TP53 102_292del [DNA binding domain deletions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
TP53 102_292del [DNA binding domain deletions] Added
TP53 334_346del [Tetramerization domain deletions], Mutation Effect, Description Updated
TP53 334_346del [Tetramerization domain deletions], Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
TP53 334_346del [Tetramerization domain deletions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
TP53 334_346del [Tetramerization domain deletions] Added
TP53 334_346ins [Tetramerization domain insertions], Mutation Effect, Description Updated
TP53 334_346ins [Tetramerization domain insertions], Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
TP53 334_346ins [Tetramerization domain insertions], Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
TP53 334_346ins [Tetramerization domain insertions] Added
TP53 V218dup, 102_292mis [DNA binding domain missense mutations], 102_292ins [DNA binding domain insertions], 102_292del [DNA binding domain deletions] Deleted
TP53 334_346del [Tetramerization domain deletions], 334_346ins [Tetramerization domain insertions] Deleted
USP1 Amplification, Mutation Effect, Description Updated
USP1 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
USP1 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
USP1 Amplification Added
XPA Truncating Mutations, Mutation Effect, Description Updated
XPA Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
XPA Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
XPA Truncating Mutations Added
XPA Y148D, Mutation Effect, Description Updated
XPA Y148D, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
XPA Y148D, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
XPA Y148D Added
XPA R228*, Mutation Effect, Description Updated
XPA R228*, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
XPA R228*, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
XPA R228* Added
XPA M113I, Mutation Effect, Description Updated
XPA M113I, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
XPA M113I, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
XPA M113I Added
XPA D114Y, Mutation Effect, Description Updated
XPA D114Y, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
XPA D114Y, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
XPA D114Y Added
ZRSR2 Truncating Mutations, Mutation Effect, Description Updated
```

### Evidence

```
ABCB1 Gene Type, Oncogene Updated
ACVR2A Gene Type, Oncogene Updated
ACVR2A Gene Type, Tumor Suppressor Updated
ADGRA2 Gene Type, Oncogene Updated
ALK F1245Y, Neuroblastoma, Lorlatinib, Description Updated
ALK F1245Y, Neuroblastoma, Lorlatinib, FDA Level Updated
	 New: Fda3
	 Old: no
ALK F1245Y, Neuroblastoma, Lorlatinib, Level Updated
	 New: 3A
	 Old:
ALK F1245Y, Neuroblastoma, Lorlatinib, Propagation to Other Liquid Tumor Types Updated
ALK F1245Y, Neuroblastoma, Lorlatinib, Propagation to Other Solid Tumor Types Updated
ALK F1245Y, Neuroblastoma, Lorlatinib 3A Added
ALK F1174C, Neuroblastoma, Lorlatinib, Description Updated
ALK F1174C, Neuroblastoma, Lorlatinib, FDA Level Updated
	 New: Fda3
	 Old: no
ALK F1174C, Neuroblastoma, Lorlatinib, Level Updated
	 New: 3A
	 Old:
ALK F1174C, Neuroblastoma, Lorlatinib, Propagation to Other Liquid Tumor Types Updated
ALK F1174C, Neuroblastoma, Lorlatinib, Propagation to Other Solid Tumor Types Updated
ALK F1174C, Neuroblastoma, Lorlatinib 3A Added
ALK F1174L, Neuroblastoma, Summary Updated
ALK F1174L, Neuroblastoma, Lorlatinib, Description Updated
ALK F1174L, Neuroblastoma, Lorlatinib, FDA Level Updated
	 New: Fda3
	 Old: no
ALK F1174L, Neuroblastoma, Lorlatinib, Level Updated
	 New: 3A
	 Old:
ALK F1174L, Neuroblastoma, Lorlatinib, Propagation to Other Liquid Tumor Types Updated
ALK F1174L, Neuroblastoma, Lorlatinib, Propagation to Other Solid Tumor Types Updated
ALK R1275L, Neuroblastoma, Summary Updated
ALK R1275L, Neuroblastoma, Lorlatinib, Description Updated
ALK R1275L, Neuroblastoma, Lorlatinib, FDA Level Updated
	 New: Fda3
	 Old: no
ALK R1275L, Neuroblastoma, Lorlatinib, Level Updated
	 New: 3A
	 Old:
ALK R1275L, Neuroblastoma, Lorlatinib, Propagation to Other Liquid Tumor Types Updated
ALK R1275L, Neuroblastoma, Lorlatinib, Propagation to Other Solid Tumor Types Updated
ALK R1275L, Neuroblastoma Added
ALK R1275L, Neuroblastoma, Lorlatinib 3A Added
ALK R1275Q, Neuroblastoma, Summary Updated
ALK R1275Q, Neuroblastoma, Lorlatinib, Description Updated
ALK R1275Q, Neuroblastoma, Lorlatinib, FDA Level Updated
	 New: Fda3
	 Old: no
ALK R1275Q, Neuroblastoma, Lorlatinib, Level Updated
	 New: 3A
	 Old:
ALK R1275Q, Neuroblastoma, Lorlatinib, Propagation to Other Liquid Tumor Types Updated
ALK R1275Q, Neuroblastoma, Lorlatinib, Propagation to Other Solid Tumor Types Updated
ALK R1275Q, Neuroblastoma Added
ALK R1275Q, Neuroblastoma, Lorlatinib 3A Added
ALK F1245V, Neuroblastoma, Summary Updated
ALK F1245V, Neuroblastoma, Lorlatinib, Description Updated
ALK F1245V, Neuroblastoma, Lorlatinib, FDA Level Updated
	 New: Fda3
	 Old: no
ALK F1245V, Neuroblastoma, Lorlatinib, Level Updated
	 New: 3A
	 Old:
ALK F1245V, Neuroblastoma, Lorlatinib, Propagation to Other Liquid Tumor Types Updated
ALK F1245V, Neuroblastoma, Lorlatinib, Propagation to Other Solid Tumor Types Updated
ALK F1245V, Neuroblastoma Added
ALK F1245V, Neuroblastoma, Lorlatinib 3A Added
ALK F1174C, Neuroblastoma, Summary Updated
ALK F1174C, Neuroblastoma Added
ALK F1245Y, Neuroblastoma, Summary Updated
ALK F1245Y, Neuroblastoma Added
ALK Fusions, Other Tumor Types, Summary Updated
ALK C1156Y, Non-Small Cell Lung Cancer, Summary Updated
ALK G1269A, Non-Small Cell Lung Cancer, Summary Updated
ALK F1174C, Other Tumor Types, Summary Updated
ALK F1174C, Other Tumor Types Added
ALK F1174L, Neuroblastoma Added
ALK F1174L, Other Tumor Types, Summary Updated
ALK F1174L, Other Tumor Types Added
ALK G1202R, Non-Small Cell Lung Cancer, Summary Updated
ALK G1202R, Other Tumor Types, Summary Updated
ALK L1196M, Non-Small Cell Lung Cancer, Summary Updated
ALK L1196M, Other Tumor Types, Summary Updated
ALK L1196M, Other Tumor Types Added
ALK R1275L, Other Tumor Types, Summary Updated
ALK R1275L, Other Tumor Types Added
ALK R1275Q, Other Tumor Types, Summary Updated
ALK R1275Q, Other Tumor Types Added
ALK F1245V, Other Tumor Types, Summary Updated
ALK F1245V, Other Tumor Types Added
ALK F1245Y, Other Tumor Types, Summary Updated
ALK F1245Y, Other Tumor Types Added
ARAF Oncogenic Mutations, Erdheim-Chester Disease, Summary Updated
ART1 Gene Type, Oncogene Updated
BCL2L2 Gene Type, Oncogene Updated
CEBPA P272_R358ins [bZIP Region In-Frame Insertions], P272_R358del [bZIP Region In-Frame Deletions], R300G, AML with Biallelic Mutations of CEBPA, Prognostic Summary Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Description Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Description Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, FDA Level Updated
	 New: Fda2
	 Old: Fda3
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Level Updated
	 New: 1
	 Old: 3A
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Propagation to Other Liquid Tumor Types Updated
EGFR 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Summary Updated
EGFR L858R, Non-Small Cell Lung Cancer, Summary Updated
EGFR L858R, Other Solid Tumor Types, Summary Updated
EGFR 729_761del [Exon 19 in-frame deletions], Other Solid Tumor Types, Summary Updated
ELL2 Gene Type, Oncogene Updated
ELL2 Gene Type, Tumor Suppressor Updated
ERBB2 Amplification, Breast Cancer, Trastuzumab Deruxtecan, Description Updated
ERBB2 Amplification, All Solid Tumors, Trastuzumab Deruxtecan, Description Updated
FGFR3 IGH-FGFR3 Fusion, Plasma Cell Myeloma, Diagnostic, Description Updated
FGFR3 IGH-FGFR3 Fusion, Plasma Cell Myeloma, Diagnostic, Level Updated
	 New: Dx2
	 Old:
FGFR3 IGH-FGFR3 Fusion, Plasma Cell Myeloma, Diagnostic Summary Updated
FGFR3 IGH-FGFR3 Fusion, Plasma Cell Myeloma, Prognostic, Level Updated
	 New: Px1
	 Old: Px2
KRAS G12D, All Solid Tumors, ASP3082, Description Updated
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Non-Small Cell Lung Cancer, Elzovantinib, Capmatinib, Tepotinib, Description Updated
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Non-Small Cell Lung Cancer, Elzovantinib, Capmatinib, Tepotinib, FDA Level Updated
	 New: Fda3
	 Old: no
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Non-Small Cell Lung Cancer, Elzovantinib, Capmatinib, Tepotinib, Level Updated
	 New: 4
	 Old:
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Non-Small Cell Lung Cancer, Elzovantinib, Capmatinib, Tepotinib, Propagation to Other Liquid Tumor Types Updated
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Non-Small Cell Lung Cancer, Summary Updated
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Non-Small Cell Lung Cancer, Elzovantinib, Capmatinib, Tepotinib, Propagation to Other Solid Tumor Types Updated
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Non-Small Cell Lung Cancer Added
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Non-Small Cell Lung Cancer, Elzovantinib, Capmatinib, Tepotinib 4 Added
MET H1094Y, Non-Small Cell Lung Cancer, Elzovantinib, Propagation to Other Liquid Tumor Types Updated
MET H1094Y, Non-Small Cell Lung Cancer, Elzovantinib, Level Updated
	 New: 3A
	 Old:
MET H1094Y, Non-Small Cell Lung Cancer, Elzovantinib, FDA Level Updated
	 New: Fda3
	 Old: no
MET H1094Y, Non-Small Cell Lung Cancer, Elzovantinib, Propagation to Other Solid Tumor Types Updated
MET F1200I, Non-Small Cell Lung Cancer, Summary Updated
MET F1200I, Non-Small Cell Lung Cancer, Elzovantinib, Description Updated
MET F1200I, Non-Small Cell Lung Cancer, Elzovantinib, FDA Level Updated
	 New: Fda3
	 Old: no
MET F1200I, Non-Small Cell Lung Cancer, Elzovantinib, Level Updated
	 New: 3A
	 Old:
MET F1200I, Non-Small Cell Lung Cancer, Elzovantinib, Propagation to Other Liquid Tumor Types Updated
MET F1200I, Non-Small Cell Lung Cancer, Elzovantinib, Propagation to Other Solid Tumor Types Updated
MET F1200I, Non-Small Cell Lung Cancer Added
MET F1200I, Non-Small Cell Lung Cancer, Elzovantinib 3A Added
MET H1094Y, Non-Small Cell Lung Cancer, Summary Updated
MET H1094Y, Non-Small Cell Lung Cancer, Elzovantinib, Description Updated
MET H1094Y, Non-Small Cell Lung Cancer Added
MET H1094Y, Non-Small Cell Lung Cancer, Elzovantinib 3A Added
MET H1094Y, Other Tumor Types, Summary Updated
MET H1094Y, Other Tumor Types Added
MET F1200I, Other Tumor Types, Summary Updated
MET F1200I, Other Tumor Types Added
MET Amplification, Other Tumor Types, Summary Updated
MET Fusions, All Solid Tumors, Summary Updated
MET Fusions, All Solid Tumors, Crizotinib, Propagation to Other Solid Tumor Types Updated
MET Fusions, Other Tumor Types, Summary Updated
MET Fusions, Other Tumor Types Added
MET Y1003, Non-Small Cell Lung Cancer, Summary Updated
MET Y1003, Other Tumor Types, Summary Updated
MET Y1003, Other Tumor Types Added
MET Oncogenic Mutations, Other Tumor Types Name Changed
	 New: Other Tumor Types
	 Old: All Tumors
MET Oncogenic Mutations, Other Tumor Types, Summary Updated
MET D1010, 963_1010splice [Exon 14 splice mutations], 963_1010del [Exon 14 in-frame deletions], Exon 14 Deletion, Other Tumor Types, Summary Updated
MET D1010, 963_1010splice [Exon 14 splice mutations], 963_1010del [Exon 14 in-frame deletions], Exon 14 Deletion, Non-Small Cell Lung Cancer, Summary Updated
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Other Tumor Types Added
MET N1100S, V1092I, H1106D, R1170Q, M1250T, Other Tumor Types, Summary Updated
NSD2 IGH-NSD2 Fusion, Plasma Cell Myeloma, Diagnostic, Description Updated
NSD2 IGH-NSD2 Fusion, Plasma Cell Myeloma, Diagnostic, Level Updated
	 New: Dx2
	 Old:
NSD2 IGH-NSD2 Fusion, Plasma Cell Myeloma, Diagnostic Summary Updated
NSD2 IGH-NSD2 Fusion, Plasma Cell Myeloma, Prognostic, Description Updated
PIK3CA Oncogenic Mutations, All Solid Tumors, Summary Updated
RET Fusions, Thyroid Cancer, Selpercatinib, Description Updated
USP1 Gene Type, Oncogene Updated
XPA Gene Type, Tumor Suppressor Updated
```
